Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF
复制标题
DOI：
10.1002/ejhf.900
复制
发表时间：
2017-10-01
影响因子：
18.2
通讯作者：
Zannad, Faiez
中科院分区：
文献类型：
--
作者：
Ferreira, Joao Pedro;Rossignol, Patrick;Zannad, Faiez
盐皮质激素受体拮抗剂（MRA）被推荐（除非禁忌）用于所有射血分数降低的心力衰竭（HFrEF）患者。然而，MRA在常规临床实践中仍未得到充分利用。本研究的目的是描述的决定因素和模式的使用MRA在HFrEF.Methods和结果BIOSTAT-CHF是一个欧洲多中心，前瞻性研究，招募患者次优治疗血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂（ACEi/ARB）和/或β-受体阻滞剂，以优化这些药物的使用指南为基础的目的。从最初的2516名受试者中，这项回顾性事后分析包括了1325名有MRA治疗指征的患者（即左心室射血分数35%，估计肾小球滤过率≥ 30 mL/min/1.73m（2），K+
Aims Mineralocorticoid receptor antagonists (MRAs) are recommended (unless contraindicated) to all patients with heart failure with reduced ejection fraction (HFrEF). However, MRAs are still largely underused in routine clinical practice. This study aims to describe the determinants and pattern of use of MRAs in HFrEF.Methods and results BIOSTAT-CHF is a European multicentre, prospective study which enrolled patients suboptimally treated with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs) and/or beta-blockers, with the aim of optimizing guideline-based use of these agents. From the original 2516 subjects, this retrospective post hoc analysis included the 1325 patients with an indication for MRA therapy (i.e. left ventricular ejection fraction 35%, estimated glomerular filtration rate >= 30 mL/min/1.73m(2), K+